Acorda Therapeutics receives marketing approval from FDA for AMPYRA Acorda Therapeutics.

Dedicated and experienced customer support agents shall be available to help healthcare professionals procedure prescriptions, work with insurance carriers to facilitate protection, and help individuals to access benefits obtainable through reimbursement assistance and affected individual assistance programs. AMPYRA Patient Support Services could be reached at 888-881-1918 for more information about AMPYRA. The FDA authorized AMPYRA with a risk mitigation and evaluation strategy system comprising a medication guidebook and communication plan. The goals of the communication plan are to inform patients about the significant risks, including seizures, associated with use of higher than recommended dosages of AMPYRA therapy, and the noticeable change of the established name from fampridine to dalfampridine.Costantino, Dr.P.H., Eduardo R. Pajon, M.D., Louis Fehrenbacher, M.D., James N. Atkins, M.D., Jonathan Polikoff, M.D., Victor G. Vogel, M.D., M.H.S., John K. Erban, M.D., Priya Rastogi, M.D., Robert B. Livingston, M.D., Edith A. Perez, M.D., Eleftherios P. Mamounas, M.D., M.P.H., Stephanie R. Property, Ph.D., Patricia A. Ganz, M.D., and Norman Wolmark, M.D.1,2 The contribution of cyclophosphamide to these regimens is not defined. Initial evaluations of taxanes in the adjuvant setting up used a sequential strategy of administration after completion of the anthracycline-based regimen.3,4 These research provided the explanation for the National Surgical Adjuvant Breast and Bowel Project B-30 trial.